I trade the calendar, not the story.

The production schedule has not yet acknowledged what the retail data has been saying since spring.



Contracts signed this year carry both higher day rates and better cost-recovery terms than the backlog they replace. The mix improves mechanically for two years.
Contracts signed this year carry both higher day rates and better cost-recovery terms than the backlog they replace. The mix improves mechanically for two years.
The latest development phase came in ahead of schedule and under budget. Full-cycle breakeven for the block is now low enough to turn the dividend into a lower-beta instrument.
No disagreement about the product. The valuation requires flawless manufacturing scale-up and full payer coverage simultaneously.
The subsidy was the crutch and it is no longer load-bearing in the markets that set the price.
A meaningful share of the backlog was priced before the input cost move and cannot be repriced. Those contracts convert at materially lower margin.
The production schedule has not yet acknowledged what the retail data has been saying since spring.
Book-to-bill is not the problem. Turning the book into revenue on schedule is, and the schedule has moved.